Adaptive Biotechnologies has entered into a collaboration with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. Adaptive will use its immune profiling assay, immunoSEQ, to identify potential biomarkers in cells of cancer patients to assess the impact of treatments on the immune system and to identify patient populations more likely to respond to targeted therapies. The assay uses high throughput next-gen sequencing to characterize T and B cell receptors.
"We are delighted to collaborate with Bristol-Myers Squibb to help uncover immunological biomarkers of response to cancer agents," said Chad Robins, chief executive officer and Founder of Adaptive Biotechnologies. "Collaborating with Bristol-Myers Squibb is a real win for companies like ours that are committed to deepening the understanding of the interaction between the host immune system and the cancer cells themselves."